Blog Archives

The development of biological therapeutics has led to remarkable clinical benefits in many indications. But, despite this success, the induction of anti-drug antibodies (ADAs) due to the potential immunogenicity of these therapeutics, remains a significant challenge to the successful development of biotherapeutics. In their paper, Dr Karen Hill and Dr Gary Bembridge of Abzena discuss the impact of immunogenicity and approaches that can be taken in pre-clinical development to reduce the effect on product success and patient experience. ...